Xaira Therapeutics IPO

Xaira Therapeutics is an integrated biotechnology company utilizing AI that aims to transform the treatment of disease. The company has a mission to rethink the drug discovery and development process by honing in on machine learning research, expansive data generation, and robust therapeutic product development. Xaira Therapeutics was founded by Arvind Rajpal, David Baker, Don Kirkpatrick, Hetu Kamisetty, Joe Watchwell Watson, and Marc Tessier-Lavigne in 2024 and is headquartered in San Francisco, CA.

Buy or sell Xaira Therapeutics stock Learn more about Xaira Therapeutics stock

Learn more about Xaira Therapeutics

Is Xaira Therapeutics a publicly traded company?

Xaira Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Xaira Therapeutics go IPO?

Xaira Therapeutics has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Xaira Therapeutics's IPO price?

The IPO price for Xaira Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Xaira Therapeutics pre-IPO?

Xaira Therapeutics is privately held company and is not publicly traded, therefor investing in Xaira Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Xaira Therapeutics shares?

To determine the value of your Xaira Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Xaira Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Xaira Therapeutics before it goes public?

Yes, you can seek to sell shares in Xaira Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Xaira Therapeutics's funding to date?

Xaira Therapeutics has raised $1B to date.

When was Xaira Therapeutics founded?

Xaira Therapeutics was founded in 2024.

Who are Xaira Therapeutics's major investors?

Sequoia Capital

New Enterprise Associates

SV Angel

Lightspeed Venture Partners

Menlo Ventures

Lux Capital

Arch Venture Partners

Two Sigma Ventures

Byers Capital

R-Squared Ventures

Parker Institute for Cancer Immunotherapy

WRF Capital

Xaira Therapeutics funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
4/23/2024	Series A and Seed	$1B raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.